GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BriaCell Therapeutics Corp (TSX:BCT) » Definitions » Cash Receipts from Fees and Commissions

BriaCell Therapeutics (TSX:BCT) Cash Receipts from Fees and Commissions


View and export this data going back to 2006. Start your Free Trial

What is BriaCell Therapeutics Cash Receipts from Fees and Commissions?

Cash Receipts from Fees and Commissions only applicable to companies reporting Cash Flow from Operations in direct method.


BriaCell Therapeutics Business Description

Industry
Traded in Other Exchanges
Address
235 - 15th Street, Suite 300, 3rd Floor, Bellevue Centre, West Vancouver, Vancouver, BC, CAN, V7T 2X1
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
Executives
Jamieson Bondarenko Director
Marc Lustig 10% Security Holder, Director
Gadi Levin Senior Officer
William Williams Director, Senior Officer